Authors

Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University

Latest:

Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLC

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

Suresh S. Ramalingam

Latest:

Dr. Ramalingam on the Efficacy of Trastuzumab Deruxtecan in HER2+ NSCLC

Suresh S. Ramalingam, MD, FASCO, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive non–small cell lung cancer.

Suresh S. Ramalingam, MD

Latest:

Unveiling the Plenary and Gynecologic Cancer Abstracts: Drs Ramalingam and O'Malley

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Suresh S. Ramalingam, MD, Emory University

Suresh S. Ramalingam, MD, Emory University School of Medicine

Suresh S. Ramalingam, MD, FASCO

Latest:

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.

Suresh S. Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University

Latest:

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

Suresh S. Ramalingam, MD, Winship Cancer Institute

Latest:

Updates in Immunotherapy for Advanced Thoracic Malignancies

Suresh S. Ramalingam, MD, Winship Cancer InstitutePanelists: Benjamin P. Levy, MD, Sibley Memorial Hospital

Suresh Senan, MD, VU University Medical Center

Suresh Senan, MRCP, FRCR, PhD, VU University Medical Center

Suriya Jeyapalan, MD, MPH, Tufts Medical Center

Susan A. McCloskey, MD

Latest:

Dr. McCloskey on Postoperative Radiation in Patients With Breast Cancer

Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.

Susan C. Modesitt, MD, FACS, FACOG

Latest:

Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian Cancer

Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Susan C. Pannullo, MD, Weill Cornell Brain

Susan Domchek, MD

Latest:

Dr Domchek on the Importance of Germline Testing in Breast Cancer Care

Susan Domchek, MD, FASCO, discusses the importance of germline testing in breast cancer care.

Susan E. Prockop, MD

Latest:

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ Lymphomas

Susan E. Prockop, MD, pediatric oncologist, Memorial Sloan Kettering Cancer Center, discusses tabelecleucel in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphomas.

Susan F. Slovin, MD, PhD

Latest:

Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center

Susan Galbraith, MD, PhD

Latest:

Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.